Shandong Science ›› 2020, Vol. 33 ›› Issue (6): 34-43.doi: 10.3976/j.issn.1002-4026.2020.06.006

• Pharmacology and Toxicology • Previous Articles     Next Articles

Mechanisms of the drug pair Astragali Radix-Scutellariae Barbatae Herba in treating lung cancer based on network pharmacology

HOU Yue1, LI Qiang2, WANG Dai-jie 2, CUI Li 2, ZHENG Xin 1, 3*   

  1. 1.School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China; 2.Shandong Analysis and Test Center, Qilu University of Technology(Shandong Academy of Sciences),  Jinan 250014, China; 3.Qingdao Haici Medical Group, Qingdao 266033, China

  • Received:2020-03-19 Online:2020-12-09 Published:2020-12-10

Abstract: We aimed to determine the mechanism of Astragali Radix-Scutellariae Barbatae Herba (AR-SBH) medicine in treating lung cancer. The active ingredient and target protein of the drug pair AR-SBH and lung cancer-related disease targets were searched through a database. The drug-compound-target and compound-target-disease networks were constructed. A protein-protein interaction(PPI) network of key targets was established, followed by analysis using R software for gene ontology(GOand Kyoto Encyclopedia of Genes and Genomes(KEGG key target enrichment. Sixteen effective active ingredients of the drug pair AR-SBH were obtained, which acted on 111 lung cancer-related targets. Key targets included TP53, AKT1, MAPK, TNF, VEGFA, and IL-6. GO enrichment analysis mainly involves RNA transcription, inflammation, extracellular, and nuclear. KEGG signaling pathway mainly includes TLR, NLR, HIF-1, FoxO, PI3K-Akt, and other pathways. AR-SBH plays a role in treating lung cancer by inhibiting inflammation, signal transduction, angiogenesis, and other processes. The results predict the molecular mechanism of AR-SBH in lung cancer treatment and lay a foundation for further in-depth study on the pharmacological effects of the drug pair AR-SBH.

Key words: Astragali Radix-Scutellariae Barbatae Herba; lung cancer, network pharmacology, tumor necrosis factor

CLC Number: 

  • R285